Theromics Inc. has appointed Andrew C. Zeringue as Chief Executive Officer. Zeringue brings nearly 18 years of leadership experience in interventional oncology, thermal ablation, and the commercialization of innovative medical technologies. He has worked on advancing emerging technologies from FDA clearance through commercialization and large-scale market adoption.
Theromics is developing biomaterial technologies aimed at improving energy delivery and treatment consistency in minimally invasive cancer therapies. The company is currently advancing its HeatSYNC™ gel platform, designed to enhance thermal energy transfer during ablation procedures, toward FDA clearance and clinical adoption.
Also read: WHO and Gilead Sciences renew partnership to accelerate visceral leishmaniasis elimination
“We reviewed many candidates for this position and Andrew’s extensive experience in interventional oncology and thermal ablation quickly distinguished him as the right choice to steer Theromics into its next chapter,” said Joseph Amaral, Chairman of the Board of Theromics.
Before joining Theromics, Zeringue held senior leadership roles at Quantum Surgical, NeuWave Medical (Ethicon/Johnson & Johnson), BTG, and AngioDynamics. He also co-founded MedTech Angels, an investment group supporting early-stage FDA-regulated medical device companies.
“I believe Theromics is uniquely positioned to help advance the next generation of local tumor therapy,” said Andrew C. Zeringue. “The company’s founders are internationally recognized thought leaders in interventional oncology, and I am honored to join them in their mission to reduce recurrences following ablation therapy.”
